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PREFACE 
The great breakthrough in the understanding of diabetes 
was the demonstration that acute diabetes followed 
pancreatectomy. Thereafter, the isolation and purification 
of insulin brought life to diabetics, \^o without it faced 
death. Pancreatic islets of Langerhans represent a unique 
cluster of different types of cellular populations 
responsible for the biosynthesis and release of their 
characteristic hormones. Coordinated regulation of these 
hormones is vital for the maintenance of various metabolic 
regulations in the body especially the homeostasis of 
glucose. Thorough knowledge of the islets and its various 
cell types is, therefore, a must for understanding the 
mechanism through which a well balanced interaction of 
various peptide hormones of the iselts brings about this 
delicate and vital biological effect. Introduction of oral 
hypoglycemics give new hope for normalization of blood 
glucose in adult onset diabetes. 
Despite the intensive work, and many historical 
discoveries, the etiology and pathogenesis of diabetes 
mellitus shall remains to be fully elucidated. 
In the studies presented in this dissertation attempts 
have been made to have some insights into the insulinogenic 
and hypoglycemic properties of some plant materials as well 
as some synthetic analogues of c-terminal tetrapeptide of 
cholecystokinin (cck-4), studies on some insulin like 
properties of (-) epicatechin have also been presented in 
the present studies. 
The tetrapeptides and the plant materials described in 
this disseration appears to be promising compounds to be 
explored, with the view to developing new drugs for the 
control of type II diabetes. 
REVIEW OF LITERATURE 
The islets of Langerhans are complex, interactive 
endocrine units in a supporting matrix of connective tissue 
with a rich vascular network. The endocrine pancreas of 
normal adult rat constitute 1-2 percent of the total 
pancreatic mass, consisting of 2000 islets of Langerhans 
(Hellman, 1959) with a mean diametert of 100-200 vim (range 
50-300 um) (Zimmy and Backard, 1975). They are recognizable 
as spherical ovoid, olliptical or irregular aggregates of 
cells (about 5700 cells) per islet (Green and Taylor? 1972) 
dispersed throughout in the pancreatic exocrine parenchyma 
with a slight preponderance in the tail (splenic) portion of 
the pancreas. 
Cellular Composition of the Endocrine Pancreas 
Histological, immunocytochemical and ultrastructural 
studies have demonstrated that human or rat islets are 
composed of 70-80 percent insulin producing beta cells that 
reside largely in the interior of the islet, 15-20 percent 
glucagon producing A-cells or pancreatic polypeptide 
containing PP-cells arranged in the priphery and 5-10 
percent somatostatin containing D-cells that are dispersed 
throughout the islets. This morphological arrangement 
consisting of a central core of beta cells may be 
functionally important for the component endocrine cells to 
modulate their hormone release (Stefan et al., 1982). 
Several excellent staining techniques exist for the 
demonstration of the B-cells in preparation for light 
microscopy, namely chromium hematoxylin and aldehyde fuschin 
procedures of Gomori (1939, 1941, 1950), the victoria Blue 
method of Ivic (1959), and the Pseudo-isocyanine technique 
of schiebber and Schiessler (1969). For the demonstration 
of A and D cells, these methods are less satisfactory since 
in the Gomori procedures both A and D-cells are stained in 
red with phloxine. To distinguish between these two types 
of non B-cells, a thricrome staining can be used (Bencoxme, 
1952; Lazarus and Volk, 1962). 
A wide variety of silver impregnation techniques has 
also been applied to the endocrine pancreas to demonstrate 
non B-cells more distinctly. Creutzfeldt (1953) and Gepts 
(195 7) argued that the Gros-Schultze as well as Holmes 
procedure, do not only stain all non B-cells, but a 
variable number of B-cells as well. Hellerstorm and Hellman 
(1960) claimed that with their modification of the 
Davenport technique less A-cells are stained than with the 
Gomori methods. They called Aj-cells those cells that did 
take up silver, and A„-cells those that remained unstained. 
The four types of cells were called: A, B, C, and D cells 
(Deconinck et al., 1971; 197 2). It was pointed out that 
cells equivalent to D and D^ cells are normally present in 
the gastroduodenal mucosa. Recently it was reported that 
cells identical to pancreatic A-cells also occur in the same 
mucosa in some species (Unger and Orci, 1975; Dobbs et al. 
1975; Larsson et al. 1975). B-cells on the other hand have 
never been detected in the gut mucosa of mammals. 
Specific Functions of the Islet Cells 
It has been accepted since a long time that B-cells 
are responsible for insulin production and release. A-cells 
secrete glucoagon (Hellman and Taljedal, 1972), and the D-
cells secreting somatostatin inhibit the secretion of 
insulin and glucagon (Alberti et al. 1973; Chen et al. 
1974). In the pancreatic islets, the close topographical 
relationship of the somatostatin containing cells with B and 
A-cells evokes the possibility of a local regulation of the 
release of insulin and glucagon by these cells. 
The Beta-Cell 
The beta cell is probably the most extensively studied 
cell type of the islets due to the importance of its 
secretory product, insulin. Using immunofluorescent and 
histochemical techniques, several investigators have 
reported that in the beta cells, the beta granules contain 
insulin (Misugi et al. 1970; Ernaldson et al. 1975). 
It is now well established that normal function of the 
islet Beta-cell is to synthesize, store and release the 
anabolic hormone, insulin (Howell 1984; Orci; 1986). 
Functions 
Insulin was first recognized as a powerful stimulus to 
the permeation and utilization of glucose by various 
sensitive tissues (Levine and Goldstein, 1955). In addition 
Insulin Induced Changes in the Metabolic Patterns in Liver 
Muscle and Adipose Tissue 
Tissue Metabolic Action effector enzyme/carrier 
Liver Glycogen synthesis (+) 
Gluconcogenesis (-) 
Glycogen synthetase (a) 
Phosphoenol pyruvate 
carboxykinase (i) 
Glucose-6-phosphatase(i) 
Muscle Glucose uptake (+) 
Glycogen synthesis {+) 
Amino acid accumula-
tion ( + ) 
Amino acid incorpora-
tion in protein 
Glucose transport (a) 
Glycogen synthetase (a) 
Not known 
Not known 
Adipost 
tissue 
Glucose uptake (+) 
Glycogen synthesis (+) 
Fatty acid synthesis 
Lipolysis 
Glucose transport (a) 
Glycogen synthetase (a) 
Pyruvate dehydrogenase (a) 
Acetyl CoA carboxylase (a) 
Hormone sensitive lipase (i) 
(+) increased 
(-) decreased 
(a) activated 
(i) inhibited 
t.o its antidiabetic or hypoglycemic action, the hormone also 
strongly influences the biosynthesis as well as the 
breakdown of major food stuffs, i.e. carbohydrates. 
Proteins and lipids (Krahl, 1961; Steiner, 1966; Fritz; 
1972; Steiner and Freinkel 1972). The main target tissues 
of insulin are the liver, muscle and adipose tissues. In 
liver, which is insulin's major target tissue, insulin 
decreases glycogenolysis, gluconeogenesis and ketogenesis 
and increases glycogen and fatty acid synthesis. Insulin 
induced changes in the metabolic patterns in liver, muscle 
and adipose tissues appear to be due to alterations in the 
activities of the certain key rate limiting enzymes and 
transport system, as outlined below:(Table). 
The possibility that insulin acts by binding to its 
target tissues was first suggested by stadic et al. (1953) 
on the basis of the uptake of iodo insulin by isolated rat 
hemidiaphragms i^ vitro. Antioniades and Gershoff (1966) 
and Crofford (1968) demonstrated insulin uptake by isolated 
fat cells and attributed this rapid reaction to an 
association of the hormone with the plasma membrane. 
Binding of iodoinsulin to receptors in the plasma membranes 
of its target cells has been directly demonstrated (House, 
1971). Kono and Braham, 1971; Cuatrecasas, 1971a; Freychet 
et al. 1971). The correspondence between the relative 
biological potencies of various insulin analogues and their 
relative abilities to compete with iodoinsulin for receptor 
binding (Freychet e+ al. 1974; Gammeltoft and Glieman 1973; 
Simon et al. 1974), suggests that the association between 
the insulin and its receptors is the physiologically 
significant one. 
Insulin action in the target tissues is primarily and 
essentially dependent upon the binding of t.he hormone to 
specific cell membrane receptors (Freychet; 1977) and 
probably to the intracllular binding sites too (Hovart et 
al. 1975; Goldfine and Smith, 1976). The resultant hormone 
receptor interaction initiates specific intracellular events 
such as inhibition of cAMP-dependent protein kinase, 
activation of phosphoprotein phosphatase and deph 
osphorylation of mitochondrial pyruvate dehydrogenase, which 
lead to the activation of the effector enzymes such as 
glycogen synthetase and pyruvate dehydrogenase (Larner and 
villar Palasi 1971; Larner et al. 1978; Lawrence and Larner 
1978; Oron et al. 1979). It was suggested that a 1200-1500 
dalton hypotetical peptide of the target cells may translate 
the hormone receptor interactions into the intracellular 
molecular event (Larner et al. 1980). The identity and mode 
of action of this translator is not known. 
Insulin Biosynthesis 
A distinctive feature of the process of insulin 
biosynthesis is the intracellular proteolytic conversion of 
precursor to the hormone prior to its storage an secretion 
from the beta cells (Steiner 1967, 1978). Insulin is 
BETA GRANULE FORMATION 
R.E.R. 
PROINSULIN 
(S-S Bond 
formation) 
PROINSUL IN 
EMIOCYTOSIS 
(EXOCYTOSIS) 
AMINO ACIDS 
TRANSFER RNA 
ATP.GTP, Mg++ 
Enzymes 
' L.^ANTIMYCIN BLOCKS 
)'T^—TRANSFER STEP 1 
* (energy dependent) 
TRANSFER STEP 2 
10-20 Min 
-EARLY GRANULES 
PROGRESSIVE 
CONVERSION 
(f 1/2= ' ^ Ihour ) 
MEMBRANE 
RECYCLING 
20 Min 
_ ! _ 
30-120 Min 
HOURS-DAYS 
J_ 
TRANSFER STEP3 
(Energy dependent 
Ca-<-+- dependent) 
SECRETED PRODUCTS 
INSULIN \ 
C-PEPTIDEi94V. 
PROINSULIN I o./ 
INTERMEDIATED *"• 
Zn + + 
OTHERS? 
FiguAt U Scktmatic ^ummaA.y oi thz insulin bio^yntkztic 
mackina.A.y od thz pancAZatic bzta czli^ (R.E.R. 
= Aough zndopla.4>mic AZticuium; M.l/. = micAovz^i-
ciz4>} (SlzinZA, 19761. 
synthesized initially as the preproinsulin at the rough 
endoplasmic reticulum (RER) of beta-cell (Patzelt et al. 
1978) and it comprises the major biosynthetic product in the 
microsomal fraction (Sorensen et al. 1970). Variety of 
secreted proteins are synthesized initially with amino 
terminal extensions of 20-30 amino acid residues (Milstein 
et al. 1972; Kemper et al. 1974; Boime et al. 1975). These 
extensions appear to serve as the "Signal regions" for the 
binding of polyribosomes to the rough endoplasmic reticulum 
leading to vectorial discharge of the newly formed peptides 
into the cisternae of endoplasmic reticulum (Blobel and 
Sabatine, 1971). These extensions normally are rapidly 
cleared away in the microsomes but are retained when 
appropriate mRNA fractions are translated in various cell 
free systems i_n vitro. The molecular weight of the bovine 
and rat preproinsulin is approximately 11,500-12000. 
Preproinsulin have 23, additional amino acids at the amino 
terminus {Chan, et al. 1976). These preproinsulins appear 
to be converted to proinsulin so rapidly under normal 
conditions that they escape detection (Lernmark et al. 
1976). Preproinsulin is then converted to proinsulin by the 
removal of pre-signal sequence in the cavities of RER. The 
molecule is then transferred to the Golgi appratus via 
vesicles of RER (Orci, 1974; 1982; 1985) by an energy 
requiring mechanism (Sharp et al., 1975). The Golgi complex 
is said to be involved in the initiation of proteolytic 
maturation of proinsulin to insulin (Orci, 1974; Steiner et 
al. 1970, 1974, 1976). Using electron microscope 
autoradiography, Orci (1986) was able to show that trans 
Golgi cisternae and secretory granules of beta-cells in 
their initial stage are coated with a protein named 
clathrin. Experimental evidences suggest that the coated 
granules play a critical role in the conversion of 
proinsulin to insulin and maturation of proinsulin. 
Conversion of Proinsulin to Insulin 
The mechanism of formation of biologically active 
insulin from proinsulin within the beta-cells is not clear 
This complex process requires a selective proteolysis of 
proinsulin (Orci et al. 1985). Conversion of proinsulin to 
Insulin begins with the initial cleavage of the connecting 
segment at either its N or C terminal to produce the two 
chain intermediates with the molecular weight approximately 
that of proinsulin (Tung and Yip, 1969). With time the 
other terminal is cleaved and the C-peptide is released. 
Thus during biologic proteolysis the two basic amino acids 
at either end of C-peptide, i.e. Arg 31, 32; Lys 62, 63; are 
removed and free biologically inactive C-peptide is 
ultimately released from beta-cells (Rubenstein and Steiner, 
1970) . 
The conversion process requires the activity of 
probably, two proteolytic enzymes; trypsin-like enzyme and 
carboxypeptidase-B with pH-optima between 5.4 and 6.5 
(Kemmler et al. 1972). These proteases appeared to be 
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localized in granules and/or their membrane sacs. The 
cytochemical demonstration of these enzyme activities in 
the granules located in the immediate vicinity of actively 
packaging Golgi succules, indicates that the enzymes are 
probably Golgi derived (Smith, 1972). 
The direct identification of the intracellular site 
where proinsulin is proteolytically processed into insulin 
has been achieved by immunocytochemistry using a proinsulin 
specific monoclonal antibody (Orci, 1986). Insulin 
immunoreactivity is absent from the golgi stack of the 
pancreatic beta cells and first becomes detectable in 
clathrin coated secretory vesicles (Orci, 1986), released 
from the trans golgi pole Clathrin coated secretory vesicles 
transform into mature non coated secretory granules which 
contain the highest concentration of insulin immunoreactive 
sites. Maturation of clathrin coated secretory vesicles is 
accompanied by a progressive acidification of vesicular 
millieu, as evidenced by a cytochemical probe that 
accumulates in acidic compartments whereupon it can be 
revealed by immunocytochemistry (Orci, 1986). Thus 
packaging of prohormone by enrgy dependent process into 
secretory vesicles and acidification of this compartment 
are critical steps in the proper proteolytic maturation of 
insulin. Once proteolysis of proinsulin begins in intact 
cells, the reaction becomes independent of energy exchange 
(Steiner, 1967). 
11 
Pulse chase experiment in the presence of monensin 
showed that radioactivity was accumulated in the clathrin 
coated secretory granules, whereas mature non coated 
secretory granules showed a/H^ evel of radioactivity as 
compared to control.. Moreover, 47% decrease in the 
radioactive insulin was observed at the end of 85 minute 
chase period under monensin treatment (Orci et al., 1984a). 
Replacement of Lysine and Arginine by their respective 
analoge (Canavine and Thialysine ) resulted into strongly 
labelled clathrin-coated granules and weakly labelled non 
coated granules. Moreover, only 11% of radioactive products 
was detected as insulin, as compared to 78% in controls 
(Orci, 1984b). These observations indicate the impairment 
of proinsulin conversion and accumulation of radioactive 
secretory products in a clathrin-coated Golgi related 
compartment of beta-cell. Hence conversion of proinsulin is 
linked to its unpurturbed passage through clathrin coated 
compartment and subsequent maturation of later into non-
coated secretory granules. 
The Insulin Storage Granule 
The beta granule is the primary storage site of the 
finished insulin (Grodsky, 1970) and a direct 
correlationship has been reported between the degree of 
granulation and their insulin content. The structure of the 
granule is well established (Howell, 1982). In quantitative 
terms the major protein component of the beta-granule, apart 
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from insulin, is the detached C-peptide vjhich is present in 
equimolar amounts with insulin but it is unclear to vSiat 
extent its presence will affect the crystallization process 
(Howell, 1984). 
The size of individual storage granule (0.2-0.3 um) is 
very small but their size necessitates the storage of very 
large numbers of granules - 13,000 in each beta cell (Dean, 
1973). The question as to Whether the beta granule merely 
plays a passive role as a storage container for insulin or 
whether the granule itself plays an active part in its own 
extension, remains to be resolved (Orci & Malaisse, 1980; 
Yaseen et al., 1983; Button & Peshawasia, 1982). 
Intracellular Transport of Insulin 
Evidences are now available to show that insulin 
(alongwith equimolar concentration of C-peptide) is released 
into the extracellular space by exocytosis of the secretory 
granules or emiocytosis (Orci, 1974; Lacy, 1975; Cerasi, 
1975). Before the release, the storage/secretory granule 
has shown to be transported to the cell mentorane by a system 
of contractile action like microtubules (Lacy et al., 1968; 
Malaisse et al., 1972; Pipeleers et al., 1976). The 
secretory granule subsequently lie close to the cell 
membrane, a feature commonly called 'Lining up' or 
margination' and the granule sac soon fuses with the cell 
membrane, opens-up to release the granule content into the 
extracellular space. While the fusion of the granule sac 
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with the cell membrane is supposed to be under the control 
of microfilamentous cell web (Orci et al., 1972), the 
fission of the fused membranes apparently is mediated, as 
demonstrated recently, by certain 'chemi-osmotic' changes 
(Hermans & Henquin, 1986). The conformation and contraction 
of the microtubular microfilamentous system as well as other 
secretion related cellular phenomena are apparently 
modulated by intracellular and transmembrane fluxes of (Ca 
(Flatt et al., 1980). After the release of their contents, 
the empty membranes sacs of secretory granules become 
pinched off into the cy+oplasm as pinocy+otic microvesicles. 
These vesicles are either returnd to the golge canplex or 
fuse with lysosomes (Meda, 1978) and becomes degraded (Lacy, 
1975). 
Although morphological evidences amply demonstrate 
emiocytosis as the major mode of insulin release, it was 
however found insufficient to explain the certain 
quantitative and qualitative aspects of insulin release, 
even in basal conditions. An alternative mode of insulin 
release such as intracellular dissolution of grcinules in the 
hyalopasm and the subsequent diffusion of insulin into the 
extracellular space has been suggested by Fukuma (1974). 
Factors Influencing Insulin Secretion 
Agents provoking insulin release are designated as 
initiator or stimulators and those that are ineffective 
14 
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alone but increase the secretory response to an initiator 
are referred to as potentiators or secondary stimulators. 
cAMP has been shown to have a marked potentiating effect on 
the ability of glucose to stimulate insulin release from 
islets. In addition intracellular concentration of cAMP can 
be modestly increased by stimulatory concentrations of 
glucose (Charles et al., 1973; Grill & Cerasi, 1974; Capito 
& Hedeskov, 1974). However, the mechanism by v»^ ich glucose 
affects the cAMP content in islets is not known. 
Some evidences suggest that the raised intracellular Ca 
concentration in response to glucose is responsible for 
stimulation of adenylate cyclase. The effect of glucose in 
increasing cAMP depends on the presence of extracellular Ca 
(Charles et al., 1975; Hellman, 1976). It has been reported 
that Ca calmodulin stimulates rat adenylate cylase activity 
(Valverde et al., 1979; Sharp et al., 1980). However, since 
Ca calmodulin fails to affect mouse islet adenylate cyclase 
(Thams et al., 1982), Ca Calmodulin activation of 
adenylate cyclase does not seem to be a plausible mechanism 
for glucose stimulation of adenylate cyclase. 
It has been demonstrated that isolated B-cells 
exhibits a markedly lower cAMP formation than do B-cells in 
intact islet. Glucose alone does not influence cAMP 
concentration in purified B-cells, but enhances glucagon 
induced cAMP formation in these cells, suggesting that this 
lack of glucose stimulation is caused by the separation of 
B-cells from glucagon containing A-cells (Schmit and 
17 
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Pipeleers, 1985). Similarly, somatostatin produced in islet 
D-cells, which inhibit cAMP accumulation in islets (Bent-
Hansen et al., 1979) may be involved in the paracrine 
regulation of B-cell function. 
Protein kinase-c dependent pro+ein phosphorylation has 
been identified in pancreatic islets (Lord & Ashcroft, 1984; 
Thams et al., 1984) and glucose has been found to induce 
protein kinase-c mediated protein phosphorylation in 
neonatal islets (Dunlop & Larkins, 1986). 
Neural Influences 
Insulin secretion is directly influenced by the central 
nervous system, Woods and Porte in 1974 showed that 
sympthetic and Parasympathetic nervous system may be 
modulators of alpha and beta cell of islets of Langerhans. 
Some hormonal peptides such as gut hormones, gastrin and 
cholecystokinin play important roles as neuroregulators. 
These are located in central (Dockray, 1976; Larsson and 
Rehfeld, 1977; Mueller et al., 1977; Rehfeld, 1978a; 1978b; 
Larsson and Rehfeld, 1979) and peripheral nerves (Unvas-
Wallensten et al., 1977; Larsson and Rehfeld, 1979). They 
are synthesized in neuronal tissue (Goltermann, et al., 
1980). Their major physiological influences are probably 
indirect (Vanlane et al. , 1974 and Schat-z et al . , 1973). 
Alteration in insulin secretion can occur in spontaneous 
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hyper (Maracek and Feldman, 1973) and hypothyroidisn 
(Renould et al., 1974). 
Changes in insulin secretion occur during pregnancy 
(Saudek et al., 1975), the estrous cycle (Bailey and Matty, 
1972) and after the administration of oral contraceptives 
(Spellacy et al., 1972). Progesterone administration 
elevates basal insulin level and insulin response to glucose 
(Kalkhoff et al., 1970). Estrogen (Spellacy et al., 1972) 
and testosterone (Bailey and Matty, 1972) does not affect 
islet function. 
Glucocorticoids have no effect on _in vitro islet cell 
function but prolonged exposure to these are concentrated in 
synaptic vesicles from where they are released like other 
neurotransmitters (Emson et al., 1980). CCK-nerve terminals 
are present in pancreatic islets (Larsson and Rehfeld, 
197 9). It seems that C-terminal tetrapeptide amide Trp-Met-
Asp. Phe-NH is predominant form of CCK- in these nerves. 
It is referred to as CCK-4 and is common to both CCK and 
gastrin. Rehfeld (1971) studied the effect of various 
cholecystokinins and gastrin and found that CCK-4 was more 
effective in releasing insulin in man - and in mammals 
(Rehfeld et al., 1980). He further observed that the 
tetrapeptide amide has a neural control on secretion of 
insulin and other islet hormones. Rehfeld et al. (1980) CCK 
is structurally and functionally related to gastrin and 
perhaps has a common evolutionary origin (Larsson and 
Rehfeld, 1977). Biological activity of this peptide is due 
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to C-t.erminal sequence and the remaining part modify their 
potency on various target, tissues. On studying the effect 
of different forms of CCK on insulin release Rehfeld et al., 
1980 found that all of them stimulate the secretion of 
pancreatic hormones and that the CCK-4 v/as the most 
effective one. It was effective even at dilution of 10 M. 
The intact tetrapeptide amide with free Trp and Phe-NHj 
termini seemed necessary for biological activity. 
In more recent studies, cholecystokinin has been shown 
to augment the insulin response to hyperglycemia in rats 
(Sakamoto, 1982; Zawalich, 1986; Rosseti, 1987) and dogs 
(Hermansen, 1984) but not in pigs (Lindkaer et al., 1981). 
In rat pancreatic islets, specific CCK-binding sites have 
been demonstrated (Sakamoto et al., 1985; Verspohl et al., 
1986. Whether cholecystokinin, which is released after 
ingestion of amino acid and fat containing meals (Liddle et 
al. , 1985; Owyang et al., 1986; Go et al., 1970; ), 
may act as insulinotropic hormone in man.is less clear. 
Experimental Diabetes Mellitus 
Streptozocin (STZ), a methyl nitroso urea with a 2-
substituted glucose, is a pancreatic • B-cell toxin that has 
been widely used to induce experimental diabetes mellitus. 
Streptozocin is isolated from streptomyces acromogenes and 
have a dose related diabetogenic effect but the diabetogenic 
dose varies considerably between different species (Rerup, 
22 
1970; Cooperstein, 1981). Its mechanism of action has not 
been fully elucidated. In single high dose , STZ is 
aaent 
believed to act as an alkylating/and damage the DNA of 
cells (Okomoto, 1985; LcDOUX, 1984; LcDOUX, 1986). Studies 
examining the effects of multiple injections of low (i.e. 
subdiabetogenic)doses of STZ in certain strains of mice 
suggest that the thymus dependent, cellular immune systems 
may be involved in at least part STZ;s diabetogenic effect 
(Like, 1976; Buschard, 1978; Paik, 1980; Shin, 1981). The 
type of diabetes induced by streptozocin depends upon the 
route and frequency of administration. thus, neonatal rats 
administered a single intraperitoneal injection of 90 mg/kg 
body weight of streptozotocin develop persisten 
hyperglycemia by 6th week of age and subsequently a diabetic 
condition more a less similar to human NIDDM. 
INTRODUCTION 
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Since a long time man has been using plant constituents 
in various forms for the treatment of different ailments. 
With the advancement of knowledge, the importance of plant 
constituents as source of unlimited natural wealth, 
especially in the form of drugs and essential oils has been 
increasingly recognized. The use of different plant 
constituents as drugs is common in our country especially in 
Ayurvedic and Unani system of medicine. However, 
investigations on the clinical uses of the plant 
constituents have only recently been started in various 
laboratories. India being a vast country having extreme 
geographical and climatic diversities provides innumberable 
plant species and is therefore, ideally suited for 
scientific investigations on their clinicl properties. 
Herbs and plant extracts have also been traditionally 
used for controlling diabetes mellitus in folk medicine all 
over the world. It has been reported recently that the bark 
of Ptrocarpus marsupium Roxb had been used successfully in 
Indian medicine for the treatment of diabetes (Chakravarthy 
et al., 1980). The active antidiabetic principle of the 
plant was suggested to be a benzopyran, (-) epicatechin 
(Devon et al., 1975; Sawhney et al., 1956) which protects 
normal rat islets from alloxan toxicity, brings about 
normalization of blood glucose level, and helps B-cell 
regeneration after necrosis due to alloxan (Chakravarthy et 
al., 1981). Recently Charles and Simon (1984) have reported 
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that. (-) epicatechin, when administered to rat increases 
insulin secretion and also raises insulin content of islets. 
The present studies describe , for the first time 
insulin like effect of (-) epicatechin. It stimulates 
14 incorporation of U -C glucose into glycogen of rat 
diaphragm, increases oxygen uptake in various insulin target 
tissues and inhibits lipolysis in epididymal fat pads. To 
understand the nature of binding site of (-) epicatechin on 
125 the target cells, competitive binding studies with I-
insulin have been carried out. These studies indicate that 
the receptor for the binding of (-) epicatechin on the 
target cell rhembrane is different from that of insulin. 
Annona squamosa (Sharifa) is a small tree of the 
natural order Annonaceae, which is cultivated almost all 
over ' India for its fruits. Water extract of the Annona 
squamosa leaves has been used as insecticidal and 
anthelmintic . The present studies on the effects of this 
water extract on the lowering of blood glucose level have 
received some interesting results in normal and 
streptozotocin diabetic rats. Also, insulinogenic 
properties of an analogue of cholecystokinin have been 
presented. Insulin secretion is directly influenced by the 
central nervous system, Woods and Porte in 1974 showed that 
sympathetic and parasympathetic nervous system may be 
modulators of alpha and beta cell of islets of langerhans. 
Some hormonal peptides such as gut hormones, gastrin and 
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cholecystokinin play import-ant role as neuroregulators. 
CholecystoXinin, a gastrointestinal hormone has been 
implicated as neurotransmitter influencing insulin release 
from the islets. Rehfeld et al. (1980) studied the 
molecular nature of CCK-nerve terminals • present in the 
pancreatic islets. The prominent form of CCK in these 
nerves seem to be the C-terminal tetrapeptide amide, Trp-
Met-Asp-Phe-NH-^ of cholecystokinin referred to as CCK-4. 
It was observed that amongst various cholecystokinins, CCK-4 
was considerably more effective in releasing islet hormones. 
Synthetic analogues of C-terminal tetrapeptide amide of 
cholecystokinin (CCK-4) in which N-terminal Trp residue was 
substituted by cyclic amino acid Glp or Pro retain the 
ability to stimulate the release of insulin from the 
isolated islets of langerhans (Ahmed et al., 1984). These 
analogues were, however, foud to have completely lost the 
ability to stimulate glucagon release. 
We have studied the biological activities of three new 
congeners of CCK-4 (Trp-Met-Asp-Phe- NH3). 
Peptide I Trp-Met-Asp-Me-Phe 
II Trp-Ser-Asp-Me-Phe 
I I I Pro-Met-Asp-Phe-NHCH3 
In peptide I , c-terminal residue Phe of CCK-4 i s 
methylated Peptide, I I , has two modifications i . e . in 
addition to methylated C-terminal Phe residue. Met a t 
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position 2 is also replaced by Ser. The third analogue 
Pep+ide III, has also two modifications. Trp being replaced 
by Pro at position one and the C-terminal cimide is 
methylated. The three molecules of CCK-4 differ from the 
parent molecule CCK-4 as well as from each other with 
respect to their effects on the release of insuliun and 
glucagon from the isolated islets of Langerhans. Perifusion 
experiments were also carried out for studying insulin 
release from islets of Langerhans with CCK-4 and peptide 
III. It has been observed that CCK-4 and peptide III 
stimulates the release of insulin at stimulatory dose of 
glucose (20 mM) at. 37 C in static incubation as well as in 
perifusion. The effect was temperature and dose dependent. 
When peptide III (Pro-Met-Asp-Phe-NHCH, ) was injected 
intravenously to normal ratsfor testing the hypoglycemic 
property of the peptide it caused significant lowering of 
the blood glucose level in normal rats in a dose related 
manners. 
MATERIALS AND METHODS 
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Materials 
(-) Epicat.echin, collagenase type V, Aprot.inin 
(Trasylol), bovine serum albumin (BSA)- were obtained from 
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Sigma Chemicals U.S.A. I-insulin (specific activity 100 
14 
Ci/gm) , U - C-glucose (specific activity 255 mCi/mrnole) and 
insulin radioimmunoassay kit were purchased from Bhabha 
Atomic Research Centre, Bombay, India. Glucagon kit was 
obtained from Diagnostic products corporation, Los Angeles, 
U.S.A. 
Bovine zinc insulin (6 times crystallized) was 
obtained from Boots Drug House, Bombay, India. C-terminal 
tetrapeptide amide of cholecystokinin (CCK-4) and its 
synthetic analogues were synthesized in the Biopolymers 
Division of Central Drug Research Institute, Lucknow, India. 
Annona squamosa leaves were obtained from National 
Botanical Research Institute, Lucknow, India. Amino acids, 
PPO and POPOP were product of Sisco Research Laboratories, 
Bombay, India. All other reagents and chemicals used were 
of analytical grade (AR). 
Animals 
Animals used in the present studies were derived from 
the animal colony of Central Drug Research Institute, 
Lucknow, housed in air-conditioned rooms. Charles Foster 
albino male ra-t-s maintained on standard balanced pellet 
(Hindustan Lever, Bombay, India) - and water ad libitum were 
used throughout the experiments. 
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Methods 
Isolation of Islets of Langerhans from Rat Pancreas 
The animals were fasted overnight before they were 
sacrificed for the removal of pancreas. The islets of 
Langerhans were isolated by collagenase digestion method of 
Lacy and Kostianovsky (1967). Albino male rats of desired 
weight were injected with pilocarpine (60 mg/kg b.w.) 
intraperitoneally, 2 hr before sacrificing the animal for 
the removal of pancreas. The rats were decapitated and the 
pancreas were gently removed by carefully cutting from the 
splenic part towards the duodenal part or Vice versa. The 
pancreas was placed in a beaker with ice cold modified 
Hank's balanced salt solution. After cleaning off the 
extraneous adipose tissue, the tissue was chopped into small 
pieces. The fine pieces were washed several times with HBSS 
following removal of fats. The chopped tissue was allowed 
to settle down and then collagenase 4 mg/ml of packed tissue 
was added. Incubation was carried out in scintillation 
vials. The vials were incubated with vigorous stirring 
horizontally for 15-20 minutes at 37 °C in a metabolic 
shaker. The incubation was terminated by adding 10 ml of 
HBSS containing 1 per cent BSA to the vials. The islets 
were picked up by means of a past.eur pipette under 
dissection microscope and transferred in Kreb's Ringer 
Bicarbonate buffer (KRB) containing 3 mg/ml bovine serum 
albumin, 12 naturally occuring amino acids, plus 0.01 M non 
essential amino acids according to Eagle (1959). 
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The time of incubation and concentration of collagenase 
were standardized for each batch of collagenase. 
Incubation of Islets with Peptides 
Groups of 5 islets of comparable size were placed into 
a flask containing 1 ml of Kreb's-Ringer-bicarbonate buffer 
with 2% bovine serum albumin, 2 mM Glucose, 12 naturally 
occuring amino acids plus 0.01 M non essential amino acids 
according to Eagle (1959) and Trasylol (1000 KlU/ml). The 
incubation was carried out at 37 C, pH 7.4 for 1 hr in a 
metabolic shaker (72 oscillations per minute) in an 
atmosphere of 9 5% 0 and 5% ^'^2' 
Samples were drawn from the media after the ccxnpletion 
of incubation period for the assay of insulin and glucagon 
employing the methods of Morgan and Lazarow (196 3) and 
Hazzard et al. (1968) respectively with minor modifications 
v^erein polyethylene glycol was used to separate bound and 
free antigen. 
Studies on the Hypoglycemic Properties of the Peptide Pro-
Met-Asp-Phe-NHCH 3 
Charles Fost-er albino ra^s weighing 200-250 gm were 
used for the study. The animals were divided into two 
groups, normal control and peptide treated group. Ten rats 
were taken in each group. 
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Glucose-tolerance Test 
Glucose tolerance test was carried out according to 
Duffy et al. (1973) using 1.75 gm glucose per kg body 
weight. Treated group was given intravenous injection of 
the peptide (5,10,15,30 mg/kg b.w.). The blood was 
withdrawn at zero, half, one and three hours after glucose 
administration. Glucose was estimated by the glucose-
oxidase peroxidase method of Huggot and Nixon (1957). 
Perifusion of Islets of Langerhans with Synthetic Analogues 
of CCK-4 
o 
Islets were preincubated for 30 minute at 37 C in 
medium containing 2 mM glucose. Groups of 50 islets were 
then placed on a nylon filter and perifused by using a 
Pharmacia Perstaltic Pump Po with medium containing 2 and 20 
mM glucose according to Charles & Simon (1984). Perifusion 
started with a flow rate of 5 ml/min for 5 min at 4 °C to 
wash out insulin transferred with the islets as well as 
insulin secreted before the start of perifusion. The flow 
rate was then adjusted to 1 ml/min and temperature raised to 
37 °C. Fractions of 2 ml were collected. An initial 5 
fractions were collected to allow a basal secretion to be 
established. Perifusion was continued with media containing 
2 mM and 20 mM glucose, with or without peptide. All 
fractions collected were later assayed for insulin content. 
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Prepara t ion of Fat Ce l l s 
Fat. c e l l s were prepared according •^ o the method of 
Rodbell (1964). Rats were k i l l e d by d e c a p i t a t i o n , t h e 
epididyinal fa t pads were removed and r insed in 0.85% NaCl 
s o l u t i o n , and t h in d i s t a l p o r t i o n s from each pad were cut 
i n to t h r e e p i e c e s . Upto 1 gm of t i s s u e was added t o 
s i l i c o n i z e d 25 ml - f lask con ta in ing 3 ml of a lbumin-
b i ca rbona t e b u f f e r , 10 mg of co l l agenase , and 3 umoles of 
glucose per ml. Incubat ions were c a r r i e d out for 1 hr a t 
0 . . . 
37 C in a metabolic shaker. The tissue was dispersed into 
small fragments within 1 hr of incubation with collagenase. 
Fat cells were liberated from the tissue fragments by gentle 
stirring. Liberation of the cells was manifested by an 
increased turbidity in t.he medium. Fragments of tissue 
still remaining after this treatment were removed with 
forceps. The suspension of the cells was centrifuged in 
polyethylene centrifuge tubes for 1 minute at 400 x g. The 
fat cells floated to the surface, and the stromal vascular 
cells were removed by aspiration, and the fat cells were 
washed by suspending them in 10 ml of warm {37*^ C) albumin 
buffer containing the desired concentration of glucose and 
centrifuging for 1 minute at 400 x g. This procedure was 
repeated three times. Stromal vascular cells were absent by 
histological examination, from the fat cell preparation 
after three washes. Fat droplets, which may have been 
formed from the breakage of the fat cells, floated more 
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rapidly "to the surface than the fat cells and were aspirated 
from the surface, after gently stirring the cell suspension . 
Oxygen-Uptake Studies 
O2 -uptake studies were conducted in Gilson oxygraph 
(Gilson Medical Electronics Middleton, Wisconsin)- having a 
Clark type electrode assembly set up. Polarizing voltage 
applied across the probe is - 0.8 V and sensitivity knob is 
set at a reading of 160. Fat cells were isolated from rats 
by collagenase digestion method of Rodbell (1971). Tissue 
slices (Brain, Liver, Muscle) and fat cells were incubated 
in the incubation vessel in Hanks medium containing 2 mg/ml 
_3 
bovine serum albumin (BSA), 17.6 mM Glcuose, 10 M (-) 
epicatechin, or 1 mU insulin as desired. pH of the medium 
was 7.4 and temperature of the oxygraph cell was maintained 
at 30°C by circulating water both. ©2" uptake was recorded 
on a strip chart recorder and was expressed as ul O2 /mg 
tissue/hr "QOp. A separate control was run where no 
epicatechin or insulin was added. Na-azide was also used as 
a control. O^-uptake was calculated according to Ronald W. 
Estabrook (1967). 
Glycogen Biosynthesis 
Sections of diaphragms weighing about 50 mg were 
isolated from the male albino rats (100 - 150 gm) and 
incubated in Krebs-Ringer bicarbonate buffer pH 7.4 
containing 3 mg/ml bovine serum albumin (BSA) 12 naturally 
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occuring amino acids plus 0.01 M non-essential amino acids 
14 
according to Eagle (1959) with 5.6 mM Glucose, 5 uCi U - C 
glucose (sp. activity 255 mCi/m mole). Incubations were 
carried out at 37°C for 15, 30, 60, 90 minutes in a 
metabolic shaker. (-) Epicatechin was added at the 
-2 -3 -5 
concentrations of (10 , 10 , 10 M) in the incubation medium. 
Separate controls were also run where no epicatechin was 
added. At the end of incubation period, the medium was 
carefully removed. Glycogen was isolated and purified from 
diaphragm and radioactivity was assayed according to the 
method of Fontella (1984). Diaphrgam was homogenized (40 
strokes, 1500 rpm) in 0.03 N HCl (1.0 ml). Aliquots (100 
ul) of the homogenate were spread evenly on the surfaces of 
the filter paper (Whatman) 2 x 2 cm. The filter paper, 
which completely absorbs immediately into a beaker 
containing a minimum of 7 ml cold 66% (v/v) ethanol. They 
were then briefly rinsed with acetone for 5 min and dried 
under a heat lamp until the odor of acetone was no longer 
present. Filter paper was placed in a glass scintillation 
vials containing 10 ml of 0.6% (w/v) 2, 5 diphenyloxazole 
(PPO) and 0.02% (w/v) 1, 4 bis 5,-phenyl-2-oxazolyl-benzene 
(POPOP) in toluene and then were counted. 
Liver Cell Membrane Isolation 
Liver cell plasma membranes were isolated according to 
the method of Neville (1968). Sucrose concentrations are 
quite critical for the isolation of membranes. All steps 
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were carried out bet.wen 0-4°C. The procedure employed was 
as under: 
{1) 100 gm rat-.s were decapitated and livers quickly 
excised, placed in an ice cold beaker and minced with 
scissors. 
(2) 10 gm of minced liver was placed in large horaogenizer. 
Added 25 ml media. Homogenized at 4 t with 8 vigorous 
strokes of the loose pestile. Pooled hcmogenate was 
added to 500 ml media (4 C) and stirred for 3 minute, 
then filtered first through cheesecloth. 
(3) The filtered homogenate was distributed equally between 
four 250 ml centrifuge bottles and spun (1500 x g max) 
for 10 minutes. The supernatant was carefully poured 
off and while tube upside down inserted absorbant paper 
into the neck to remove excess supernatant. The 
pellets were poured off into a large hcraogenizer. 
(4) The pellets were homogenized with 3 gentle strokes of 
the loose pestle. After homogenizing, membranes were 
collected in a 13000 x g max, 10 minute, pellet. This 
pellet was washed by recentrifuging, taken up in 43% 
sucrose + 1 mM MgCJ^ and floated at 90,000 x g max for 
2 hr. The float was resuspended and applied to a 37-
15% sucrose gradient containing 1 mM MgCl2. 
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I-Insulin Binding to Liver Membrane 
I - insulin (specific activity 100 Ci/g) was used for 
binding +o liver membranes according to the method described 
by Rodbell et al. (1971). In 1 mM KHCO3 was taken purified 
plasma membrane containing 150 ug protein and incubated at 
30 °C for 20 minutes with or without unlabelled insulin and 
125 
(-) epicatechin. After which, sufficient I-insulin was 
added to the incubation tubes containing 50 ul of Krebs 
Ringer phoshate buffer. (Ca free), pH 7.5 (buffer 
125 
contained 3% bovine albumin) to give a final I-insulin 
concentration of 3.0 nM. After incubation for further 40 
minutes, 60 ul aliquots were removed and layered onto 250 ul 
of Kreb's Ringer phosphate buffer, pH 7.5, containing 10 
mg/ml of albumin in plastic microtubes as described by 
Freychet et al. (1971). After centrifugation (IEC-15,000 
o 
rpm) for 5 minutes at 4 C, the supernatants were discarded 
and radioactive counts of the pellets were registered. 
Release of PFA from Fat Pads i£ vitro 
Rat epididymal fat pads were isolated after killing the 
animal by decpitation. the piece of tissue (7-20 mg) was 
placed on a glass slide and cut- horizontally (using a razor 
blade) so that the cut piece was of fairly constant surface. 
It. was t.hen transferred to a small glas stoppered test tube 
and weighed. The test tube contained Kreb's Ringer 
phosphate buffer (pH 7.4) without. Ca and with 4% bovine 
albumin. Samples were incubated with 1.5 mM theophylline 
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for 90 minute at 37°C wit.h or without (-) Epicat.echin or 
insulin FFA were determined at the end of incubation period 
according to Dole's method (1956) as modified by Trout et 
al. (1960). 
Incubation of Water Extract of Annona squamosa Leaves with 
Islets of Langerhans for Studies on Insulin and Glucagon 
Release 
Groups of 5 islets were incubated with 1 ml KRB 
containing 3 mg/ml BSA, 12 naturally occuring amino acids, 
0.01 M non essential amino acids according to Eagle (1959), 
1000 KlU/ml t.rasylol and aquous extract of Annona squamosa 
was added to a final concentration of 0.05, 0.5, 1, 2, 3 
mg/ml. The glucose concentration of the medium was 2 and 20 
mM. A separate control was run in which extract was 
omitted. The incubations were a carried out in a metabolic 
o 
shaker at 37 C, pH 7.4, for 1 hr. Samples were drawn from 
the media for the estimation of insulin and glucagon by 
radioimmunoassay. Results are expressed as uU/5 islets/hr. 
Studies on the Hypoglycemic Properties of the Water Extract 
of Annona squamosa Leaves 
Annona squamosa leaves were boiled in water for one 
hour and extracted. Ex+.ract was then filtered and 
lyophilized. Lyophilized extract was used for further 
studies, 
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Doses and Administration 
Charles Foster albino rats weighing 200-250 g were 
used. The animals were divided into three groups, namely, 
normal controls, streptozotocin diabetic control and extract 
treated diabetic group. Seven rats were taken in each 
group. 
Group A Normal controls; Animals were fed with normal 
saline instead of the plant extract. 
Group B Streptozotocin diabetic control; Animals were 
injected with streptozotocin (50 mg/kg b.w. 
i.v.)' Hyperglycemia was confirmed after 4 
days of injection with the help of Ame's 
Diastix strips. 
Group C Extract treated streptozotocin group; Animals 
injected with streptozotocin intravenously. 
After the onset of hyperglycemia, rats were 
fed orally with the extract (300 mg/kg b.w.). 
Suspended in water (Single dose) daily for 
five days. 
On the 6th day, the overnight fasted rats were bled of 
0, 1, 2, 3 hrs and blood glucose was estimated according to 
the method of Huggot and Nixon (1957). Results are 
expressed as mg/dl (mg%). 
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Glucose Tolerance Test (GTT) 
Glucose tolerance test was carried out according to 
Duffy et al. (1973) using 1.75 gm glucose per kg body-
weight. The blood was withdrawn at zero, one, two, three 
hours after glucose administration. Glucose was estimated 
according to glucose oxidase peroxidase method of Huggot and 
Nixon (1957). 
Insulin Immunoassay 
Radioimmunoassay of insulin was carried out, using RIA 
kit (BARC) according to the method of Morgan and Lazarow 
(1963). Human insulin was used as the standard. 
Method: 0.3 ml EDTA-phosphate buffer (0.01 M EDTA, 0.04 
M phosphate, pH 7.4), containing 0.5% BSA (w/v) was mixed 
with 0.1 ml of standard insulin or unknown samples and 0.1 
ml of antibody (antiinsulin guinea pig serum diluted 1 : 
125 
1,000,00 times) and kept overnight at 4°C, 0.1 ml of I-" 
insulin (about 1 x 10 cpm) was then added to the sample 
mixture and was again kept for 5 minutes at 4 °C. After 
that 0.1 ml of the second antibody (antiguinea pig 
globulin raised in rabbit) was added. Antibody bound 
radioactivity was separated from unbound by precipitation in 
12% polyethylene glycol 6000. 
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Immunoassay of Glucagon 
Radioimmunoassay of glucagon was carried out, using RIA 
kit. (Diagnostic products corporation Los Angles) according 
to the method of Hazzard et al. (1968). 
Method: 0.2 ml of the sample or standard was mixed with 0.1 
ml of glucagon antiserum and incubated for 24 hours at 2-8 
o 125 
C. This was followed by addition of I-glucagon on a 
vortex mixer. the tubes were again incubated for 24 hours 
at 2-8 °C. 1.0 ml of goat antirabbit - globulin 
(Precipitating solution) was added to precipitate antigen-
antibody complex. The t.ubes were cent rifuged at 1500 x g 
for 15 minutes. Using a foam decanting rack, decant (or 
aspirate) the supernatant., retaining the precipitat.e for 
counting. Each tube was counted for 1 minute. For control, 
-^^ 125 
two total counts tubes (only I-glucagon) and two 
nonspecific binding tubes were run together with the 
experimental tubes. The results are expressed as Pg/5 
islets/hr or Pg/ml. 
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Effect of (-) epicatechin on oxygen uptake in tissues and 
fat cells in_ vitro 
The oxygen uptake in various ^.issues and fat cells of 
rats in the presence and absence of (-) epicatechin is shown 
in Figure 9. At one millimolar concentration of (-) 
epicatechin, oxygen uptake increase significantly (45 fold 
in fat cells, 2.7 fold in liver, 3.16 fold in muscle and 3 
fold in heart) as compared to the respective controls. 
However, no increase in oxygen uptake was observed in 
thecase of brain tissue. As a control, similar experiments 
were carried out with 1 mU of insulin as shown in the figure 
(9), insulin causes significant stimulation of Oxygen -
uptake (27.2 fold in fat cells, 3.64 fold in liver, 3.44 
fold in muscle and 2.3 fold in heart). Thus there is a 
comparable stimualtion of oxygen uptake at 1 mM (-) 
epicatechin and 1 mU insulin. The stimulation of oxygen 
uptake in different tissues and cells was blocked by sodium 
azide. 
14 
Effect of (-) epicatechin on incorporation of U - C glucose 
into glycogen of rat diaphragm and glycogen content in vitro 
Rat diaphragms were incubated with or without (-) 
epicatechin in KRB-Eagle's medium. (-) Epicatechin causes 
increase in the glycogen content of rat diaphragm in a dose 
dependent manner. As shown in the Figure (10), there was 
44.3, 134.43 and 310 percent increase in the glycogen 
content of rat diaphragm when incubated with increasing 
concentration of (-) epicatechin. The maximum glycogen 
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content. was observed at 10 M concentra+ion of (-) 
epicat.echin where the cont.ent. was raised from 0.334 +_ 0.075 
to 1.37 + 0.195 mg/gm of tissue (P < 0.01). 
Similarly the compound stimulat-es the incorporation of 
14 U - C glucose into glycogen of rat diaphragm m a dose 
related manner. As shown in the figure (11), there was 6, 
. 14 28, 66 and 91 percent increase m the incorporation of U - C 
-5 -4 -3 
glucose into glycogen at the concentrations 10 , 10 , 10 , 
-2 
10 M of (-) epicatechin respectively Figure (12). The 
biosynthesis of glycogen stimulated by (-) epicatechin has 
been found to be linear upto one hour of incubation Figure 
(13). 
Effect of (-) Epicatechin on Lipolysis in Epididymal Fat 
Pads in vitro 
Rat epididymal fat pads were isolted after killing the 
animal by decapitation. Lipolysis was induced by incubating 
the epididymal fat pads with 1.5 mM theophylline in KRB and 
Eagles medium with or without (-) epicatechin. As shown in 
the figure (14) (-) epicatechin causes inhibition of 
theophylline induced lipolysis in a dose dependent manner. 
Keeeping the theophylline concentration (1.5 mM) constant, 
maximum inhibition (aboiut 61%) of lipolysis was observed at 
-3 
10 M concentration of (-) epicatechin, while with 1 mU of 
insulin (in place of (-) epicatechin) 74% inhibition of 
lipolysis was observed. 
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Effect of (-) Epicatechin on the Binding of I-insulin to 
the Liver Cell Plasma Membrane 
Binding experiments were carreid ou+ by incubating rat 
-10 125 
liver plasma meinbrane with 3 x 10 M I-insulin. About 21% 
of the radoactivity was observed to bind to the membranes. 
However, addition of 10 ng/ml of native insulin caused 19% 
125 
inhibition in the binding of I-insulin . Nearly complete 
inhibition in the binding of labelled insulin was observed 
in the presence of higher concentration of native insulin 
(100 ng/ml). The compe+ititive binding of (-) epicatechin 
125 
and I-insulin was carried out with increasing 
concentration of (-) epicatechin in the medium keeping the 
125 
concentration of I-insulin constant. The results did not 
125 
show any significant change in the binding of I-insulin to 
the membranes in the presence of increasing concentration of 
(-) epicatechin (Table 1). 
Effect of (-) Epicatechin on Glucagon Release from Islets of 
langerhans in vitro 
Table 2 shows the pattern of glucagon release by (-) 
epicatechin. 1+ was observed that (-) epicatechin an 
insulinogenic compound, has no effect on glucagon release 
even at higher concentrations of the compound (1 mM) in th e 
presence of 2 mM or 20 mM glucose in the medium. 
Table 1 ^^ 
Displacement of I-insulin binding to liver membranes by 
(-) epicatechin 
Addit ions 
No addition 
Insulin 
(-) Epicate-
chin 
.T'able 2 
Effect of (-) 
langerhans in 
Glucose 
Cone . 
(mM) 
2 
do 
do 
do 
20 
do 
do 
do 
Concen 
10 n. 
100 n' 
-2 
10 M 
-3 
10 M 
lO^M 
-9 10 M 
trat. 
g/ml 
g/ml 
epicatechin 
vitro 
ion Specific bind. 
of I-insulin 
24300 + 
19650 t 
1890 + 
23700 + 
24850 + 
24900 + 
24700 + 
on glucagon 
Concentration 
Ep 
of (-
icate 
-
10-2 
10-^ 
10-^ 
-2 
10 
10-3 
10-^ 
-) 
!chin 
1150 
1060 
400 
1390 
1560 
1050 
1270 
Lng % Inhibition 
19.0 
92.0 
00.0 
00.0 
00.0 
00.0 
release from islets of 
Rate of glucagon 
release 
Pg/5 Islets/hr. 
115 + 12.5 
109 + 10.2 
121 + 15.0 
117 + 17.5 
27.5 + 5.7 
21.5 + 6.0 
23.2 + 7.9 
24. 5 + 8. 0 
53 
Insulinogenic Property of Water Extract of Annona squcunosa 
Leaves on Insulin and Glucagon Release 
Figure (15) shows the pattern of insulin release by 
wat er extract of Annona squamosa leaves. It is evident from 
the figure tha+. water extract stimulated insulin secretion 
from isolated islets of langerhans in a dose dependent 
fashion, both in the presence of 2 and 20 mM glucose in the 
medium. Dose dependent increase of insulin secretion was 
observed upto 2 mg/ml of the water extract in the medium. 
At this concentration of the extract, insulin release was 
raised from 34 j^  7.2 to 137 + 9.5 uU/5 islets/hr (P < 0.001) 
in the presence of 2 mM glucose and from 113 _t 11.5 to 351.2 
_+ 17.9 uU/5 islets/hr in the presence of 20 mM glucose (P < 
0.001). Table (3) shows that the leaves extract has no 
effect on glucagon release from the islets of Langerhans in 
the presence of 2 mM and 20 mM glucose in the medium. 
Effect of Water Extract of Annona squamosa Leaves on Blood 
Glucose Level of Rats 
Effect of feeding of aquous extract of the Annona 
squomosa leaves were shown in the Figure (16). Feeding of 
the aquous ext.ract hacl no significant lowering on the 
fasting blood sugar level in streptozotocin diabetic rats 
Injection of streptozotocin caused about 4.7 fold increase 
in the blood glucose level (P < 0.001) as compared to normal 
control rats. 
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G l u c o s e 
Cone . 
(mM) 
C o n e . o f 
Ext r a c t 
mg/ml 
R a t e o f i n s u l i n 
r e l e a s e 
uU/5 i s l e t , s / h r . 
Table 3: Effect of Water Extract of Annona squamosa Leaves 
and Glucose Concentration on Insulin and Glucagon 
Release from Islets of langerhans in vitro 
Ra+e of glucagon 
release 
Pg/5 islets/hr. 
120 + 14 
123 + 12 
119 + 17 
112 + 20 
111 + 12 
129 + 15 
20 None 121.0 + 1 2 23 + 8.0 
21 + 4.5 
29 + 7.3 
26 + 3.9 
20 + 3.0 
18 + 3.35 
None 
0 . 0 5 
0 . 5 0 
1 . 0 0 
2 . 0 0 
3 . 0 0 
2 4 . 0 + 
3 0 . 0 + 
5 1 . 5 + 
1 2 2 . 0 + 
1 3 6 . 5 + 
1 4 4 . 0 + 
3 
7 . 5 
1 2 . 5 
13 
19 
22 
o  
0 . 0 5 
0 . 5 
1 .00 
2 . 0 0 
3 . 0 0 
.  
1 2 7 . 0 
1 5 2 . 0 
2 7 7 . 0 
3 5 1 . 0 
3 5 9 . 0 
 
+ 
+ 
+ 
+ 
+ 
12
15 
15 
29 
25 
24 
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Glucose tolerance test in streptozotocin diabetic rats 
which were fed with aquous extract, showed no marked 
improvement in the glucose tolerance capacity. One hour 
after feeding of glucose, the blood glucose level in normal 
rats rose from 73.4 +3.5 to 127.9 +5.6 and as compared to 
327 + 4.5 to 543.05 ± 15.12 mg% in the case of 
streptozotocin diabetic rats. When the extract was fed to 
stretozotocin diabetic rats, there was 23.2, 32.86 and 34.3 
mg percent blood glucose lowering at. 0.5, 1, 3 hr. after the 
glucose feeding as compared to steptozotocin diabetic 
control rats. Feeding of water extract in streptozotocin 
diabetic rats had no significant effect on blood glucose 
lowering at zero hr. as compared to streptozotocin diabetic 
control rats. Glucose was orally administered to the 
animals, 30 minute after the administration of the plant 
extract. However, feeding of the aquous extract in normal 
rats showed (6.7, 8.47 and 10.56) per cent blood sugar 
lowering at 0.5i 1 and 3 hr as compared to normal control 
rats (Table 4)• 
Effect of Synthetic Analogues of Cholecystokinin (Pro-Met-
Asp-Phe-NHCH3) *-•" Glucose Tolerance of Albino Rats 
It is clear from Table (5) that fhe intravenous 
injection (10 mg/kg body weight) of the CCK-4 analogue 
effectively lowers the blood glucose level. Glucose was 
orally administered (1.75 gm/kg b.w.) to the animals, 30 
minutes after the injection of the peptide. Intravenous 
5 7 
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Table 4: Effect, of Wa+er Extract of Annona squamosa Leaves 
(300 mg/kg b.w. orallyl raiarministered 30 min 
before) on glucose tolerance (1.75 gm/kg 
orally) of Albino Rats 
Blood glucose mg/100 ml (mean +_ S. E.) 
at. time (hr .) 
0 Vir . 1/2 hr. 1 hr . 3 hr . 
Normal 73.4+3.5 127.9+5.6 lOB.5+3.2 87.9+3.5 
Control 
Treated 71.5+4.5 119.3+3.05 99.3+4.3 79.5+2.3 
% Lowering - 6.70 8.47 10.56 
of blood 
glucose 
59 
injec^ion of the peptide decreased t.he peak blood glucose 
level at- 30 min, as compared to the conf rol group of glucose 
loaded rats. Intravenous injection of the peptide produced 
a stepwise decrease in the blood glucose after each 30 
minute interval starting from 0 hour. Concentration 
dependent blood glucose lowering response of the peptide was 
observed. Injection of the peptide (5 mg/kg b.w.) caused a 
lowering of blood glucose by 3.3, 3.8 and 6.8% at 0.5, 1 and 
3 hours as compared to normal control after glucose feeding. 
However, inection of peptide (10 mg/kg body weight) caused a 
lowering of blood glucose by 7.4, 8.6 and 13.7% at 0.5, 1 
and 3 hrs. as compared to normal control after glucose 
feeding. 
Effect- of CCK-4 and its Analogue on Insulin Release from 
Perifused Islets of Langerhans 
The effect.s of CCK-4 and its synthetic analogue Pro-
Met-Asp-Phe-NHCH3 '~^^ insulin release from the perifused 
islets of Langerhans at 2 and 20 mM glucose in the medium 
are shown in Figure (17). Perifusion experiments show that 
CCK-4 and its analogue Pro-Met-Asp-Phe-NHCH3 ^^ ^ 
-6 
concentration of 10 M, raises insulin secretion from islets 
responding only when glucose concent,rat ion in the medium was 
20 mM glucose. At 2 mM glucose concentration CCK-4 and its 
analogue were not able to stimulate the secretion of 
insulin. Integrating the areas under the curves from the 
10th to 30th fraction both inclusive, show that insulin 
60 
T a b l e 5 : E f f e c t o f S y n t h e t i c A n a l o g u e o f CCK-4 ( P r o - M e t - A s p -
Phe-NHCH3) on G l u c o s e T o l e r a n c e of A l b i n o R a t s 
Mean B l o o d g l u c o s e (mg/lOO ml +_ S . E . ) 
0 h r . 1/2 h r . 1 h r . 3 h r . 
Normal 6 9 . 7 + 4 . 6 12 3 . 7 + 3 . 9 1 0 9 . 2 + 3 . 0 8 9 . 9 + 3 . 2 
C o n t r o l 
E x p e r i m e n t a l 
( i ) 10 mg/ 7 0 . 1 + 3 . 4 1 1 4 . 5 + 3 . 1 9 9 . 7 + 2 . 5 7 7 . 5 + 2 . 0 
kg b o d y wt . 
i . V . 
% l o w e r i n g - 7 . 4 8 . 6 1 3 . 7 
o f b l o o d 
g l u c o s e 
( i i ) 5 mg/ 7 0 . 5 + 2 . 3 1 1 8 . 9 + 4 . 1 1 0 5 . 6 + 3 . 0 83 . 7jf 2 . 7 
kg b o d y w t . 
i .V . 
% l o w e r i n g - 3 . 0 3 . 8 6 . 8 
o f b l o o d 
g l u c o s e 
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s e c r e t i o n r e g i s t e r s 1.07 _+ 0 .22 u U / I s l e t . / m i n a t 20 mM 
-6 
g l u c o s e c o n c e n t r a t i o n in t h e p r e s e n c e of 10 M CCK-4 a s 
compared t o c o n t r o l va lue of 0.29 j - 0.09 u U / I s l e t / m i n , w h i l e 
i t s a n a l o g u e c a u s e s t h e r e l e a s e of 0 .47 + 0 .07 u U / I s l e t / m i n 
at 20 mM g l u c o s e . 
E f f e c t o f S y n t h e t i c Analogues o f CCK-4 on I n s u l i n and 
Glucagen Release i n v i t r o 
The effect- of CCK-4 and i t s s y n t h e t i c a n a l o g u e s . 
Pept ide I : Trp-Met-Asp-Me-Phe 
I I : Trp-Ser-Asp-Me-Phe 
I I I : Pro-Met-Asp-Phe-NHCH3 
on i n s u l i n and g lucagon r e l e a s e i s shown in ( F i g u r e 18 & 19) 
r e s p e c t i v e l y . These r e s u l t s conf i rm t h a t CCK-4 i s a p o t e n t 
-10 
r e l e a s e r of b o t h t h e hormones . At a c o n c e n t r a t i o n of 10 M, 
CCK-4 r e l e a s e i n s u l i n in t h e o r d e r of 72 + 8 uU/5 i s l e t s / h r , 
t h e c o n t r o l v a l u e b e i n g o n l y 38 +_ 4 (P < 0 . 0 0 1 ) . S i m i l a r l y , 
t h e g lucagon r e l e a s e under t h e i n f l u e n c e of CCK-4 a t a 
-10 
c o n c e n t r a t i o n of 10 M was 160 _+ 10 .4 Pg/5 i s l e t s / h r . as 
compared t o t h e c o n t r o l v a l u e of 115 + 8 .9 (P < 0 . 0 1 ) . The 
s t i m u l a t i o n of t h e r e l e a s e of i n s u l i n and g lucagon from t h e 
i s l e t s by CCK-4 was dose d e p e n d e n t . Thus t h e s t i m u l a t i o n of 
- 8 
i n s u l i n r e l e a s e w i t h 10 M and 10 M c o n c e n t r a t i o n of CCK-4 
was 98 + 7.5 uU/5 i s l e t s / h r (P < 0 .001) compared t o 10~ M 
and 148 _+ 9 .4 (P < 0 .001 compared t o 10"^ M) r e s p e c t i v e l y . 
The g lucagon r e l e a s e from t h e i s l e t s at t h e CCK-4 
63 
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in vitAo glucagon ^te^ea^e. Thz AZ-
TzaTQ~~ol glucagon by CCK-4 i^ al^o 
-ihown. The 6aA4 AZpAt^cnt the mzan 
(+_ S.P.) oi 6 cxpCAimcnt^. 
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con cen t - r a t ion of 10 ^ M and 10 ^ M was 225 + 1 2 . 8 Pg /5 
i s l e t s / h r (P < 0 .005 compared t o 10 M) and 430 + 2 7 . 2 P g / 5 
Q 
islet.s/hr (P < 0.001 as cotipared to 10~ M) respectively. 
The pat-tern of insulin and glucagon release from the 
islets in the presence of peptide I and II are shown in 
Figures 18 and 19 respectively. It is clear that both the 
peptides inhibit the release of insulin and glucagon. The 
release of insulin due to peptide I at the concentration of 
10 and 10 M came down from 38 _+ 4 uU/5 islets/hr (control 
value) to 33 + 2.5 uU/5 islets/hr (P < 0.005 as compared to 
— 8 
control) and 26 + 3 (P < 0.001 as compared to 10 M) 
respectively. There was no significant release of both the 
— 8 two hormones at their concentrations below 10 M. As 
evident from these results, the inhibition of insulin and 
glucagon with peptide I and II was dose dependent. Peptide 
11 appears to be more effective as an inhibitor of insulin 
release. Thus, at concentration of 10~ M, the inhibition of 
insulin release was about 20% more than its inhibition due 
to peptide I at the same concentration. There was no much 
difference between the two analogues with respect to their 
inhibitory effect on glucagon release. 
The figures clearly show t_hat peptide III is a releaser 
of insulin and at the same time, it is also an inhibitor of 
glucagon release. Both, the stimulation and inhibition of 
the two hormones are dose dependent. At concentrations 10 
— 8 M and 10 M of this analogue, the release of insulin 
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increases from 38 +^  4 uU/5 Isle+s/hr (control) to 62 + 5.2 
uU/5 Islets/hr and 88 +_ 7.8 uU/5 Islets/hr respectively and 
the same concentration of this analogue brings down the 
release of glucagon from 115 +_ 8.9 uU/5 Islets/hr to 104 +_ 
8.9 uU/5 Islets/hr and 85 + 8.2 uU/5 Islets/hr respectively. 
DISCUSSIOH 
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Insulin Like Activity in (-) Epicatechin 
The results presented here clearly demonstrate that (-) 
epicatechin acts like insulin at various target organs. (-) 
Epicatechin causes an increased incorporation of U -C 
glucose into glycogen of rat diaphragm and increases 
glycogen content in vitro. This flavonoid influences 
glucose metabolic pathways by increasing O2- uptake in fat 
cells, muscle and liver but not in brain tissues. Sodium 
azide, an inhibitor of electron transport chain, inhibits O2 
- uptake completely, showing that oxygen is being utilized 
through the electron transport chain. Similarities in the 
activities of (-) epicatechin and insulin has been 
described as shown in the Figure (9). The insulin like 
activity of (-) epicatechin may be either due to its 
enhancing effect on the binding of insulin on its receptor 
or may be due to its own binding on some receptors on the 
target cell membranes. The receptor may either be the same 
insulin receptor or may be some different one. The nature 
of the receptor has to be investigated. 
The hypoglycemic effect of (-) epicatechin, an active 
principle of Pterocarpus marsupium has been reported by 
Chakravarthy et al. (1980). They have shown that (-) 
epica+echin injected intraperi^oneally in^ -o rats that had 
previously been made diabetic with alloxan, brought about a 
normalization of blood glucose levels together with B-cell 
regeneration. When injected into normal rats for 4 days, it 
protected the islets from the toxic effect of alloxan . 
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Charles et al. (1984) have shown that (-) epicatechin has 
direct, effect on islets of Langerhans and increases insulin 
secretion during short term static incubations and in 
perifusion. The effect, was ATP, temperature and dose 
dependent. DNA synthesis increases in islets cultured for 
4 days in the presence of (-) epicatechin. We have 
aid 
demonstrated the insulinogenic property of (-) epicatechin^ 
also its in vitro stimulation of phosphofructokinase and 
inhibition of glucose-6-phosphatase activities in the islets 
of Langerhans. 
The results presented here clearly demonstrate that (-) 
epicatechin compares well with insulin when its biological 
activities were tested on target tissues. Like insulin, the 
biological activities of (-) epicatechin are manifested 
after its binding to the target cell membrane. It is 
interesting therefore, to see vshether epicatechin shares a 
common binding sites with insulin or not. Competitive 
125 
binding experiments between (-) epicatechin and I-insulin 
suggest that the binding site for (-) epicatechin is 
different from that of insulin. Insulin like activity of (-) 
epicatechin on target tissues after its binding to the cell 
membranes may be due to its binding on some other receptors 
different from that of insulin. The presence of such a 
receptor has not been shown in the present studies. 
However, if present, it may prove to be valuable for the 
control of hypoglycemia, providing an alternate receptors in 
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the case where there is a lack of insulin receptor on the 
target tissues. 
Thus in (-) epicatechin, we find dual properties. On 
the one hand, this compound is insulinogenic, and on the 
other it binds like insulin on the target tissues causing 
the manifestation of the some biological effects on target 
tissues comparable to insulin. 
Biochemical Studies on the Hypoglycemic Properties of Water 
Extract of Annona squomosa Leaves 
In order to study the effect of water extract of Annona 
squamosa leaves on insulin release, we selected healthy 
albino rats. Since, unlike other experimental animals blood 
sugar level of the rats are fairly stable to handling. 
It is clear from the present studies that the water 
•not 
extract of Annona squamosa leaves are'effective in lowering 
blood glucose level in glucose loaded normal and 
streptozotocin diabetic rats. The extract does not 
significantly prevents a rise in the blood glucose value in 
glucose loaded rats. The extract has been found to 
significantly increase the release of insulin from the 
islets of Langerhans in a dose depenedent manner upto 2 
mg/ml, both in the presence of substimulatory dose (2 mM) 
and stimulatory dose (20 mM) of glucose. There is no effect 
of the extract on the release of glucagon when the medium 
contains substimulatory glucose concentration (2 mM) . 
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Ffowever, when the islets were incubated with the extract in 
the medium containing 20 mM glucose, there was inhibition of 
glucagon release. The factors responsible for this 
biological effect have not been identified in these studies. 
However, the indications that it possess such an activity by 
which it stimulates insulin release and at the same time 
inhibits the release of glucagon make it an important 
material for further studies with the view to finding out 
drugs for the control of type-II diabetes mellitus. 
Effect of analogues of CCK-4 on Insulin and Glucagon Release 
C-terminal tetrapeptide amide (CCK-4) which is common 
to cholecystokinin and gastrin has gained an added 
importance after its predominant presence was detected in 
the CCK-4 terminal of pancreas by Rehfeld et al. (1980). 
These authors suggested that CCK-4 might be involved in the 
regulation of islet cell function and showed that it 
stimulates the release of all the four islet hormones. The 
studies on the structure activity relationship of different 
molecular forms of CCK-4 was undertaken by us with the view 
to obtaining such analogues whose effect on the release of 
islet hormones is close to glucose which is a natural 
physiological factor for the regulation of the secretion of 
islet hormones for its own homeostasis. Rehfeld et al. 
(1980) showed that C-terminal modification of CCK-4 molecule 
results in considerable loss of its ability to stimulate the 
release of insulin glucagon and other islet hormones. The 
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results presented here show that, methylation of deaminated 
C-terminal residue of CCK-4 renders the analogue (Peptide I) 
inhibitory to the release of insulin and glucagon. 
Modification of position 2 of this analogue by substituting 
Met with Ser (Peptide II) does not have much effect on the 
nature of its activity except that the new congener is 
markedly more inhibitory to insulin release. However, when 
the C-terminal amide of this analogue was methylated, the 
new analogue (Peptide III) having double modification shows 
some very interesting results. Perifusion experiments 
clearly demonstrate that CCK-4 and peptide III stimulated 
the secretion of insulin from isolated islets of Langerhans 
during short term static incubations and in perifusion. The 
stmulation of insulin secretion has been found dose 
dependent, responding only at 20 mM glucose. Static 
incubations of the peptide III have shown inhibitory effect 
on the release of glucagon. Both, the stimulation and 
inhibition of insulin and glucagon release respectively are 
peptide's dose dependent. This dual activity of the peptide 
III on islets can be compared with that of glucose which, 
at higher level in blood, stimulates the release of insulin 
and inhibits the release of glucagon. 
Effect, of Synthetic Analogues of CCK-4, Pro-Met-As p-Phe-NHCH3 
on Glucose Tolerance i^ vivo 
Our results clearly show that the peptide Pro-Met-Asp-
Phe-NHCH3 has stimulatory effect on the release of insulin 
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and at. t-.he same time inhibitory effect on glucagon release. 
Stimulation and inhibition of insulin and glucagon by the 
peptide is dose dependent. Intravenous injection of the 
peptide was effective in lowering the peak blood glucose 
level at 30 min after glucose feeding. In treated rats, the 
blood glucose lowering was significant as ccxnpared to normal 
control rats after 3 hours of glucose feeding. A near dose 
dependent response (Upto 10 mg/kg body weight) in blood 
glucose lowering was observed. From the above it may be 
concluded that this analogue of CCK-4, lowers the blood 
sugar level after glucose feeding. The feasibility of 
developing this CCK-4 analogue as a drug for the treatment 
of type - II diabetes mellitus can only be ascertained after 
further in vivo experiments. 
SUMMARY 
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Insulin was first recognized as a powerful stimulus to 
the permeation and utilization of glucose in target tissues. 
It is now widely accepted that insulin has antidiabetic or 
hypoglycomic action. The hormone strongly influences the 
biosynthesis as well as the breakdown of the major 
foodstuffs, i.e. carbohydrates, proteins, and lipids. 
Insulin is an anabolic hormone and coordinates the action of 
other hormones which are involved in intermediatory 
metabolism such as thyroxine, growth hormone, glucagon, 
glucocorticoids, involved in the utilization of food, 
thermogenesis and tissue maintenance. Insluin acts by 
binding to its target tissues and has stimulatory effect on 
glucose oxidation in target tissues. Insulin activates the 
synthesis of glycogen, lipid, proteins, nucleic acids within 
the cells. 
In the present studies, correlation between the binding 
of insulin secretagogues and the resulting islets activities 
have been studied. In addition, insulin releasing activity 
of certain plant materials as well as synthetic compounds 
and their effects on the insulin target tissues have been 
descriebed. The results and conclusions are summarised. 
Insulin Like Activity in (-) Epicalitechin 
(i) Effect of (-) epicatechin on oxygen uptake in tissues 
and fat cells i^ vitro 
At one millimolar concentration of (-) epicatechin, 
oxygen uptake increases significantly in fat cells, liver. 
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heart, but not in brain tissues. The stimulation of oxygen 
uptake in different, tissues and ceils was blocked by sodium 
azide . 
14 
(ii) Effect of (-) epicatechin on incorporation of U-C 
glucose into glycogen in rat diaphragm and glycogen 
content in vitro 
(-) Epicatechin, when incubated with rat 
diaphragm causes an increase in glycogen content as well as 
14 
incorporation of U-C glucose into glycogen of rat diaphragm 
in vitro in a dose dependent manner. Kinetic studies show 
14 
that the incorporation of U - C glucose into glycogen of 
rat diaphragm is linear upto 1 hour. 
(iii) Effect of (-) epicatechin on lipolysis in 
epididymal fat pads in vitro 
Lipolysis induced by 1.5 mM theophylline in fat 
pads is inhibited (61%) in the presence of 1 mM (-) 
epicatechin as compared to 74% inhibition observed in the 
presence of 1 mU of insulin. 
125 
(iv) Effect of (-) epicatechin on the binding of I-
insulin to the liver cell plasma membrane 
Competitive binding experiments between (-) 
125 
epicatechin and I-insulin, does not show any significant 
125 
change in the binding of I-insulin to the liver membrane 
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indicating that the insulin like properties of the flavonoid 
are not due to its sharing of the binding site with insulin . 
2. Hypoglycemic Properties of Water Extract of Annona 
squamosa Leaves 
(i) Effect on insulin and glucagon release i£ vitro 
Extract of Annona squamosa leaves stimulates 
insulin secretion from isolated islets of Langerhans at 
basal as well as stimulatory dose of glucose in a dose 
dependent manner. However, the extract has no effect on 
glucagon release from islets of langerhans _i£ vitro. 
(ii) Effect of oral feeding on blood glucose level in 
streptozocin diabetic rats 
The feeding of water soluble extract of Annona 
squamosa leaves to streptozotocin induced diabetic rats does 
not significantly effect the blood sugar level as compared 
to untreated controls. Glucose tolerance test carried out 
on the streptozotocin diabetic rats which were fed with the 
leaves extract does not show any marked improvement in their 
blood glucose lowering capacity. 
3. (i) Effect of synthetic analogues of C-terminal 
tetrapeptide eimide of cholecystokinin on insulin 
and glucagon release from the islets in vitro 
Cholecystokinin (cck-4) has been found to be 
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highly active in releasing both insulin and glucagon from 
the isolated islets of langerhans. The stimulation of 
release of both the hormones are dose dependent. 
Introduction of double modification in the 001^ -4 molecule 
i.e. the replacement of Trp at position one by Pro and the 
methylation of the c-terminal amide, yields a compound which 
is stimulatoy to insulin release and at the Scune time 
inhibitory to the release of glucagon in a dose dependent 
manner. 
(ii) Effect of cholecystokinin and its synthetic analogue 
(Pro-Met-Asp-Phe-NHCH3) on insulin release from peri-
fused islets of langerhans at 2 and 20 mM glucose 
Perifusion experiment have shown that the cck-4 and 
its anlogue Pro-Met-Asp-Phe-NHCH3 raise insulin secretion 
from islets of langerhans at 20 mM glucose confirming the 
previous data of insulin release in static incubations. No 
increase in insulin release was observed at 2 mM glucose. 
(iii) Studies on the hypoglycermic properties of the 
synthetic analogue of cck-4 (Pro-Met-Asp-Phe-NHCH3) 
Intravenous injection of the synthetic analogue 
of cck-4 (Pro-Met-Asp-Phe-NHCH3) significantly lowers the 
blood sugar level in glucose loaded rats. 
BIBLIOGRAPHY 
77 
Ahmad, N., Sharma, S.D., Rast.ogi, A.K., Kidwai, J.R. and 
Mathur, K.B. (1984). Acta. Diabetol. Lat. XXI, 361. 
Albert.!, K.G.M.M., Christensen, S.E., Iversen, J., Seyer-
Hansen, K., Christensen, N.J., Hensen, A.P., LundbacX and 
Askov, H. (1973). Lancet, ii, 1299. 
Antoiades, H.N. and Gershoff, S.N. (1966). Diabetes 15, 655. 
Ashcroft, S.J.H., Bassett, J.M. and Randle, P.J. (1972) 
Diabetes 21 (Suppl. 2), 538. 
Bailey, C.J. and Matty, A.J. (1972), Horm. Metab. Res. _4, 
266. 
Bencosme, S. (1952). Arch. Path. 53, 87. 
Bent Hansen, L., Capito, K. and Hedeskov, C.J. (1979). 
Biochim. Biophys. Acta. 585, 2 40-2 49. 
Blobel, G. and Sabatini, D.D. (1971). Biomeiribranes 2, 193. 
Boime, I., Bogulawski, S. and Caine, J. (1975). Biochem. 
Biophys. Res. Commun. 62, 103. 
Buschand, K., Rygaard, J. (1978). Acta. Pathol. Microbiol 
Scand. Sect. C Immunol. 86, 23-27. 
Capito, K. and Hedeskov, C.J. (1974). Biochem. J. 142, 653-
658. 
Cerasi, E. (1975). Quart. Rev. Biophys. 8, 1. 
Chakravarthy, B.K., Gupta, S., Gambher, S.S. and Gode, K.D, 
(1980). Ind. J. Pharmac. 12(2), 123. 
Chakravarthy, B.K., Gupta, S., Gambhir, S.S. and Gode, K.D. 
(1981). Life Sciences 29, 2043. 
78 
Chan, S.J., Keim, P. and St.einer, D.F. (1970). Proc. Nat. 
Acad. Sci. U.S.A. 73, 1964. 
Charles, M.A., Fanska, R.,Schmidt, E.G., Forshman, P.M. and 
Grodsky, G.M. (1973). Science 179, 569. 
Charles, M.A., Lawecki, J., Pictet, R. and Grodsky, G.M, 
(1975). J. Biol. Chem. 250, 6134-6140. 
Charles, S.T.H. and Simon, L.H. (1984). Diabetes 33, 291. 
Chen, M., Smith, P.H., Woods, S.C., Johnson, D.B. and Prote, 
D.Jr. (1974). Diabetes 23, 356. 
Cooperstein, S.J., Watkins, D. In: the Islets of Langerhans. 
Cooperstein, S.J., Watkins, D., Eds. New York, Academic 
Press, 1981, p. 387-425. 
Crutzfeldt, W. (1953). Beitr. Path. Anat. 133, 113. 
Crofford, O.B. (1968). J. Biol. Chem. 243, 362. 
Cuatrecasas, P. (1971). J. Biol. Chem. 243, 6432. 
Dean, B.M. (1973). Diabetologia, 9, 115. 
Deconinck, J.E., Van Assche, F.A., Potvliege, P.R. and 
Gepts, W. (1972), Diabetologia 8, 326. 
Deconinck, J.F., Potvliege, P.R. and Gepts, W. (1971). 
Diabetologia 7, 266. 
Devon, T.K. and Scott, A. (1975). In: Handbook of Naturally 
Occuring Compounds, New York, Academic Press, pp. 174. 
Dockray, G.J. (1976). Nature 264, 568. 
Dobbs, R., Sakurai, H., Sasaki, H., Ealoona, G., Valverde, 
I., Bactens, D., Orci, L. and Unger, R. (1975). Science 
187, 544. 
79 
Dole, V.P. (1956). J. Clin. Invest. 25/ 150. 
Duffy, T., Phillips, N. and Pellagrin, F. (1973). Amer. J 
Med. Sci. 265, 117. 
Dunlop/ M.E. and Larkins, R.G. (1986). Arch. Biochem. 
Biophys. 248, 562-569. 
Eagle, H. (1959). Science 130, 432. 
Emson, P.C., Lee, C M . and Rehfeld, J.F. (1980). Life Sci. 
26(5), 2157. 
Ernaldson, S.L., Parsson, J.A., BurX, J.P., Reduk, J.A., Von 
Orden, D.E. and Orden, L.S. (1975). J. Histochem. 
Cy+ochem. 23, 666. 
Flatt, P.R., Bouquist, L. and Hellraan, B. (1980). Biochem. 
J, 190, 361. 
Fontella, T., Gracia Hermida, 0., Gracia-Fernandez, M.C. and 
Gomez Acebo, J. (1984). Revista Espanola. De Fisiologia, 
40, 77-82. 
Freychet, P. (1977). In: Diabetes J.S. Bajaj (ed.). 
Excerpta. Medica, Amsterdam, p. 180. 
Freychet, p., Brandenburg, D. and Wollmer, A. (1974). 
Diabetologia 10, 1. 
Freychet, p.. Roth, J. and Neville, D.M.Jr. (1971). Proc. 
Nat. Acad. Sci. U.S. 68, 1833. 
Fritz,I. (1972). Insulin action. Academic Press. 
Fukuma, M.J. (1974). J. Elect. Micros. (Ibkyo) 23, 167. 
Gameltoft, s. and Glieman, J. (1973). Biochim. Biophys 
Acta. 320, 16. 
80 
Gerich, J.E., Charles, M,A. and Grodsky, G.M. (1976). Ann. 
Rev. Physiol. 2£' 35 3. 
Gepts, W. (1957). Ann. Soc. Roy. Sci. Med. et. Nat. _10, 1. 
Go, V.L.W., Hofmann, A.F., Summerskill, W.J.H. (1970). J. 
Clin. Invest. 49, 1558-1564. 
Goldfine and Smith (1976). Proc. Natl. Acad. Sci. (U.S.A.) 
73, 1427. 
Gomori, G. (1950). Amer. J. Clin. Pathol. 22' 665. 
Gomori, G. (1941). Amer. J. Pathol. 11_, 395. 
Gomori, G. (1939). Am. J. Pathol. 15, 497. 
Goltermann, N., Rehfeld, J.F. and Roigard-Peterson, H. 
(1980). J. Biol. Chem. 255, 6181. 
Green, K. and Taylor, K.W. (1972). J. Endocrinol. 5A_, 317. 
Grill, V. and Cerasi, E. (1974). J. Biol. Chem. 249, 4196. 
Grodsky, G.M. (1970). Vit. & Hormone 28, 37. 
Hazzard, W.R., Crockford, P.M., Buchnan, K.D., Vance, J.E., 
Chen, R., Williams, R.H. (1968). Diabetes 17, 179. 
Hellman, B. (1976). Experientia 21' 155-157. 
Hellman, B. (1959). Acta. Pathol. Microbiol. Scand. 47, 35 
Hellman, B. and Taljedal, I.B. (1972). Histochemistry of 
the pancreatic Islet Cells In: Handbook of physiology 
Sect. 7. Endocrinology, Steiner, D. and Frienkel, N., 
American Physiological Society, Washington, D.C. 1972, p. 
91. 
Hellerstrom, C. and Hellman, B. (1960). Acta. Endocr. 35, 
418. — 
81 
Hermansen, K. (1984). Endocrinol. 114, 1770-1775. 
Hermans, M.P. and Henquin, J.C. (1986). Endocrinology 119, 
105. 
Hovart, A., Li, E. and Kahsoyannis, P.G. (1975). Biochim. 
Biophys. Acta. (Amst.), 382, 609. 
Howell, S.L. (1984). Diabetologia 26, 319. 
Howell, S.L. (1982). In: A.M. Poisner & J.M. Trifaro 
(eds.). The Secretory Granule Elsevier. Medical 
Amsterdamm, 155. 
Howell, S.L. (1984). Diabetologia ^6, 319. 
House, P.D.R. (1971). FEES Letters 1_6, 339. 
Huggot, A.G. and Nixon, D.A. (1957). Lancet. 2, 368. 
Hutton, J.C. and Peshawari, M. (1982). Biochem. J. 204, 
161. 
Ivic, M. (1959). Anat. Anz. 107, 347. 
Kalkhoff, R.K., Jacoleson, M. and Lemper, D. (1970). J. 
Clin. Endocrinol. Metab. 31, 24. 
Kemmler, W., Peterson, J.D., Rubenstein, A.H. and Steiner, 
D.F. (1972). Diabetes 21 (Suppl. 2), 572. 
Kemper, B., Habener, J.R., Mulligan, R.C., Potts, J.J.Jr. 
and Rich, A. (1974). Proc. Nat. Acad. Sci., U.S.A. 71, 
3731. 
Kono, T. and Braham, F.W. (1971). J. Biol. Chem. 246, 6210. 
Krahl, M.E. (1961). Action of Insulin in Cells. Academic 
Press, N.Y. 
82 
Lacy, P.E. (1975). Am. J. Pathol. J^, 170. 
Lacy, P.E., Howell, S.L., Young,D.A., Fink, C.J. (1968). 
Nature 219, 117 7. 
Lacy, P.E. and Kostianovsky, M. (1967). Diabetes 2_1' 987. 
Larner, J., Galasko, G., Cheng, K., De-paoli, Roach, A.A., 
Roach, P.J., Huang, L.C., Lawrence, J.C., Walkenbach, 
R.C., Oron, Y. and Cabelli, R. (1980). In: Diabetes. 
W.K. Waldhaul (ed.) Excerpta Medica. Amsterdam, p. 181. 
Larner, J. and Villar Palasi, C. (1971). Current topics in 
cellular regulation. _3' 195. 
Larner, J., Lawrence, J.C., Walkenbach, R.J., Roach, P.J., 
Hazen, R.J. and Huans, L.C. (1978). Adv. Cyc. Nuc. Res. 
9, 425. 
Lawrence, J.C.Jr. and Larner, J. (1978). J. Biol. Chem. 
253, 2109. 
Larsson, L.I. and Rehfeld, J.F. (1977). Nature 269, 335. 
Larsson, L.I. and Rehfeld, J.F. (1979). Brain Res. 165, 
201. 
Larsson, L.S., Hoist, J., Hakanson, R. and Sundler, F. 
(1975). Histochemistry 44, 281 
Lazarus, S.S. and Volk, B^W. (1962). The pancreas in human 
and experimental diabetes. Greene and Stratton, New 
York. 
LeDOUX, S.P. and Wilson, G.L. (1984). Biochim. Biophys, 
Acta. 804, 387-392. 
LeDOUX, S.P., Woodley, S.E., Pathon, N.J. and Wilson, G.L. 
(1986). Diabetes 35, 866-872. 
83 
Lernmark, A., Chan, S.J., Choy, R., Na+hns, A., Canoll, R., 
Tager, H.S., Rubenstein, A.H., Swift, H.H. and Steiner, 
D.F. (1976). In: The Peptide Hormones, Molecular and 
Cellular Aspects. CIBA Fdn. Symp. 41, 7-30. 
Levine, R. and Goldstein, M.S. (1955). Rec. Prog. Horm. 
Res. 11, 343. 
Liddle, R.A., Goldfine, I.D., Rosen, M.S., Taplitz, R.A., 
and Williams, J.A. (1985). J. Clin. Invest. 75_, 1144-
1152. 
Like, A.A. and Rossini, A.A. (1976). Science 193, 415-417. 
Lindkaer Jensen, S., Rehfeld, J.F., Hoist, J.J., Nielsen, 
O.V., Fahrenkrug, J. and Schaffalitzky de Muckadell O.B. 
(1981). Acta Physiol.Scand. Ill, 225-231. 
Lord, J.M. and Ashcroft, S.J.H. (1984). Biochem. J. 219, 
547-551. 
Malaisse, W.J., Hager, D.L. and Orci, L. (1972). Diabetes 
(Suppl. 2), 21, 594. 
Maracek, R.L. and Feldman, J.H. (1973). Endocrinol. 92, 
1604. 
Meda, P. (1978). Diabetologia 14, 305. 
Milstein, C , Brownlee, G.G., Harrison, T.M. and Mathews, 
M.B. (1972). Nature New Biology 239, 117. 
Misugi, K., Howell, S.L., Greider, M.H., Lacy, P.E. and 
Sorenson, G.D. (1970). Arch. Pathol. 89, 97. 
Morgan, C.R. and Lazarow, A. (1963). Diabetes 12, 115. 
Mueler, J.E., Straus, E. and Yalow, R.S. (1977). Proc. Natl. 
Acad. Sci. 74, 3035. 
Neville, D.M.Jr. (1968). Biochim. Biophys. Acta. 154, 540. 
84 
Okamoto, H. (1985). Bioassays 2^ , 15-21. 
Orci, L. (1986). Ann. N.Y. Acad. Sci. 488, 292. 
Orci, L. (1985). Diabetologia 2_8, 528. 
Orci, L. (1982). Diabetes ^i* 538. 
Orci, L. (1974). Diabetologia 1£, 163. 
Orci, L., Gabby, K.H. and Malaisse, W.J. (1972). Science 
175, 1128. 
Orci, L., Halban, P., Amherdt, M., Ravazzola, M., Vassali, 
J.D. and Perrelet, A. (1984a). Cell 39, 39. 
Orci, L., Halban, P., Amherdt, M., Vassalli, J.D. and 
Perrelet, A. (1984b). J. Cell Biol. 99, 2187. 
Oirci, L. and Malaisse, W.J. (1980). Diabetes 29, 943. 
Orci, L., Ravazzola, M., Amherdt, M., Madsen, O., Vassalli, 
J.D. and Perrelet, A. (1985). Cell 42, 671. 
Oron, Y., Galasko, G., Cabelli, R. and Larner, J. (1979). 
Diabetes 28, 365. 
Owyang, C , Louie, D.S., Tatum, D. (1986). J. Clin Invest. 
77, 2042-2047. 
Paik, S.G., Fleischer, N., Shin, S.I. (1980). Proc. Natl. 
Acad. Sci. U.S.A. 77, 6129-6133. 
Patzelt, c , Labrecque, A.D., Duguid, J.R., Carroll, R.J., 
Keim, P.S., Heinrikson, R.L. and Steiner, D.F. (1978). 
Proc. Natl. Acad. Sci. U.S.A. 75, 1260. 
Pierre Freychet, Jesse Roth, and David, M., Neville, Jr. 
Proc.Nat. Acad. Sci. U.S.A. 68, 1833-1837. 
85 
Pipeleers, D.J., Pipeleers Marrichal, M.A. and Kipnis, D.M, 
(1976). Science 191, 88. 
Rehfeld, J.F. (1978a). Nature 22i' "771. 
Rehfeld, J.F. (1978b). J. Biol. Chem. 253, 4022. 
Rehfeld, J.F. (1971). Acta. Endocrinol. 66, 169. 
Rehfeld, J.F., Larsson, L.I., Goltermann, N.R. and Schwartz, 
T.W. (1980). Nature 234, 33. 
Renould, A., Suerdlik, R.C. and Andrade, L.L. (1974). Horm. 
Metab. Res. 6, 13 7. 
Rerup, C.C. (1970). Pharmacol. Rev. _22' 485-518. 
Rodbell, M. (1964). J. Biol. Chem. 239, 375. 
Rodbell, M., Krans, M.J., Pohl, S.L. and Birnbaumer, L. 
(1971). J. Biol.Chem. 246, 1861. 
Ronald, W. Estabrook (1967). Methods in Enzymology. Vol. X, 
41-47. 
Rossetti, L., Shullman, G.I., Zawalich, W.S. (1987). 
Diabetes 36, 1212-1215. 
Rubenstein, A.H. and Steiner, D.F. (1970). Med. Clin. N. 
Amer. 54, 191. 
Sakamoto, C , Goldfine, I.D., Roach, E. and Williams, J.A. 
(1985). Diabetes 34, 390-394. 
Sakamoto, C , Otsuki, M., Ohki, A., Yuu, H., Yamasaki, T. 
and Baba, S. (1982). Endocrinol. 110, 398-402. 
Saudek, CD., Finkowski, M. and Knoop, R.H. (1975). J 
Clin. Invest. 55, 180. 
86 
Sawhney, P.L. and Sheshadri, T.R. (1956). J. Sci. Industr. 
Res. 15C, 154. 
Schatz, H., Maier, V., Hinz, M., Nierle, C. and Pfeiffer, 
E.F. (19 73). Horm. Metab. Res. 5, 29. 
Schiebber, T.H. and Schiessler, S. (1969). Z. Zellforsch 1^, 
445. 
Schmit. and Pipeleers, D.G. (1985). Endocrinology 117, 834-
840. 
Sharp, G.W.G., Wiedenkeller, D.E., Kaelin, D., Siegel, E.G. 
and Wollheim, C.B. (1980). Diabetes 29, 74-77. 
Sharp, G.W., Wollheim, C , Muller, W.A., Gutzeit, A., 
Trueheart, P.A., Blondel, B., Orci, L. and Renold, A.E. 
(1975). Fed. Proc. 34, 1537. 
Shin, S., Paik, S.G., Fleischer, N. In: Basic and Clinical 
Aspects of Immunity to Insulin. Keck, K., Erb, P. Eds. 
Berlin, de Gruyter, 1981, p. 303-317. 
Simon, J., Freychet, P. and Rosselin, G. (1974) 
Endocrinology 95, 1439. 
Smith, R.E. (1972). Diabetes 21 (Suppl. 2), 581. 
Sorensen, R.L., Steffes, M.W. and Lindall, A.W. (1970) 
Endocrinology 86, 88. 
Spellacy, W.N., Buki, W.C. and Berk, S.A. (1972). Am. J. 
Obst. Gynecol. 114, 378. 
Stadie, W.C, Haugaard, N. and Vaughan, M. (1953). J. Biol. 
Chem. 199, 729. 
Stefan, j., Orci, L., Malaisse-Lagae, F., Perrelet, A., 
Patel, Y. and Unger, R.H. (1982). Diabetes 31, 694. 
87 
Steiner, D.F. (1976). In: Peptide Hormone, Parison, J.A. 
(ed.)/ Macmillan Press, London, pp. 49. 
Steiner, D.F. (1967). Trans. N.Y. Acad. Sci. Ser. II 30, 
No . 1, 60 . 
Steiner, D.F. (1966). Vitamins and Hormones 24, 1. 
Steiner, D.F., Clark, L. , Nolan, C , Rubenstein, A.G., 
Margoliash, E., Melani, F. and Oyer, P.E. (1970). In: 
The Pathogenesis of Diabetes mellitus. E. cerasi and R. 
Luft (eds.) pp. 123-132. Almquist and Wiksell, Stockholm. 
Steiner, D.F., Dyguid, J.R., Patzelt, c., Qian, S.J., Quinn, 
P., Labrecque, A. and Hastings, R. (1978). In: Baba, S., 
Kancko, T. & Yanaihara, N. (eds.) Proinsulin, insulin, c-
peptide, Excerpta. Medica Amsterdam, 9. 
Steiner, D.F. and Frinkel, N. (eds.) (1972). The endocrine 
pancreas - Handbook of Physiology, Endocrinology Vol. I, 
The Williams & Wilkins Co., Baltimore, M.D. 
Steiner, D.F., Kemmler, W., Tager, H.S. and Peterson, J.D. 
(1974). Fed. Proc. 33, 2105. 
Steiner, D.F., Terris, S., Chan, S.J. and Rubenstein, A.H. 
(1976). In: Insulin. R. Luft (ed.) p. 53-103. Nordisk 
Insulin Laboratorium, Gentofte, Denmark. 
Thams, P., Capi+o, K., and Hedeskov, C.J. (1984). Biochem. 
J. 221, 247-253. 
Thams, P., Capita, K. and Hedeskov, C.J. (1982). Biochem. 
J. 206, 97-102. 
Trout., D.L., Estes, E.H. and Friedberg, S.J. (1960). J. 
Lipid Res. 1, 199. 
Tung, A.K. and Yip, C.C. (1969). Proc. Nat. Acad. Sci. 
(U.S.A.), 63, 442. 
Unger, R.H. and Orci, L.L. (1975). Lancet i, 14-
88 
Unvas-Wallensten, K., Rehfeld, J.F., Larsson, L.I. and 
Unvas, B. (1977). Proc. Natl. Acad. Sci. 74, 5707. 
Valverde, I., Vandermeers, A., Anjaneyulu, R., and Malaisse, 
W.J. (1979). Science 206, 225-227. 
VanLane, V., Yamaguichi, N., Garcia, M.J., Ramey, E.R. and 
Penhas, J.C. (1974). Endocrinol. 94, 671. 
Verspohl, E.J., Ammon, H.P.T., Williams, J.A. and Goldfine, 
I.D. (1986). Diabetes 35, 38-43. 
Woods, S.C. and Porte, D. (1974). Physiol. Rev. 54, 596. 
Yaseen, M.A., Smith, J.E., Doolabh, K. and Howell, S.L. 
(1983). Diabetologia 25, 205. 
Zawalich, W.S., Cote, S.B., Diaz, V.A. (1986). Endocrinol. 
119, 616-621. 
Zimmy, M.L. and Blackard, W.G. (1975). Cell and Tissue Res. 
164, 467. 
